Neumora Therapeutics, Inc.
NMRA
$1.63
$0.010.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.73M | -67.99M | -58.82M | -72.55M | -58.70M |
| Total Depreciation and Amortization | 19.00K | 157.00K | 157.00K | 156.00K | 160.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.91M | 8.91M | 9.68M | 9.47M | 11.42M |
| Change in Net Operating Assets | -7.60M | -525.00K | -1.36M | 29.43M | -9.03M |
| Cash from Operations | -52.40M | -59.45M | -50.34M | -33.48M | -56.16M |
| Capital Expenditure | -- | -- | 775.00K | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | 84.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.31M | 44.16M | -99.57M | 156.99M | 21.26M |
| Cash from Investing | 30.40M | 44.16M | -98.80M | 156.99M | 21.26M |
| Total Debt Issued | 18.40M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 59.00K | -- | 15.35M | 1.76M | 2.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 225.00K | -225.00K | -- |
| Cash from Financing | 18.46M | -- | 15.57M | 1.53M | 2.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.55M | -15.29M | -133.57M | 125.04M | -32.25M |